NASDAQ$VTYX
Ventyx Biosciences Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Announced financial results for the third quarter ended September 30, 2024, and highlighted recent pipeline and business progress.
Ventyx Biosciences reported a net loss of $35.2 million for the third quarter of 2024, with cash, cash equivalents, and marketable securities totaling $274.8 million as of September 30, 2024. The company believes its current funds are sufficient to support operations into at least the second half of 2026. Phase 2 trials for VTX2735 and VTX3232 are expected to initiate by year-end.
- Initiated a Phase 2a trial of VTX3232 in participants with early Parkinson’s disease during the third quarter of 2024.
- Expect to initiate a Phase 2 trial of VTX3232 in participants with obesity and additional cardiovascular and cardiometabolic risk factors by year-end.
- Expect to initiate a Phase 2 trial of VTX2735 in participants with recurrent pericarditis by year-end.
- Cash, cash equivalents and marketable securities were $274.8 million as of September 30, 2024, sufficient to fund planned operations into at least the second half of 2026.
Headline financials
Revenue & EPS history
Ventyx Biosciences · Revenue · Quarterly
$0
Forward guidance
Ventyx anticipates several key milestones, including the initiation of Phase 2 trials for VTX3232 in obesity and cardiometabolic risk factors and VTX2735 in recurrent pericarditis by the end of 2024, with clinical updates expected in 2025. The company also plans to seek a partner or non-dilutive financing to support a Phase 3 trial for tamuzimod in UC. Ventyx expects current cash resources to fund operations into at least the second half of 2026.
Tailwinds
- Potential of VTX3232 and VTX2735 to emerge as best-in-class NLRP3 inhibitors.
- Potential of tamuzimod as a best-in-disease oral agent in Ulcerative Colitis with a best-in-disease safety profile.
- Potential of VTX2735 to be the first approved oral therapy for recurrent pericarditis and to have therapeutic potential in additional chronic peripheral inflammatory diseases.
- Advancing enrollment in the ongoing Phase 2a trial of VT3232 in patients with early Parkinson’s disease.
- Current cash, cash equivalents and marketable securities are sufficient to fund planned operations into at least the second half of 2026.
Headwinds
- Potential delays in the commencement, enrollment, and completion of clinical trials.
- Dependence on third parties in connection with product manufacturing, research, and preclinical and clinical testing.
- Unexpected adverse side effects or inadequate efficacy of Ventyx’s product candidates that may limit their development, regulatory approval, and/or commercialization.
- Ventyx’s ability to obtain and maintain intellectual property protection for its product candidates.
- The use of capital resources by Ventyx sooner than expected.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q3 2024
+4.2%
Avg return
Earnings day
+7.1%
Avg return
5 days after
+13.8%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+34.4%
Q2 2022
Best reaction
-11.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -5.7% | +2.5% | -6.0% | |
| Q2 2025 | +18.4% | +20.5% | +6.8% | |
| Q1 2025 | +7.0% | +1.8% | +113.2% | |
| Q4 2024 | +9.0% | +4.2% | -16.1% | |
| Q3 2024 | -5.6% | -10.0% | +34.2% | |
| Q2 2024 | +5.6% | -0.5% | +10.9% | |
| Q1 2024 | -7.9% | -6.3% | -26.4% | |
| Q4 2023 | +32.6% | +45.0% | -6.5% | |
| Q3 2023 | -11.9% | — | — | |
| Q2 2023 | +1.9% | — | — | |
| Q1 2023 | -11.6% | — | — | |
| Q4 2022 | -8.3% | — | — | |
| Q3 2022 | -9.1% | — | — | |
| Q2 2022 | +34.4% | — | — | |
| Q1 2022 | +10.6% | — | — | |
| Q2 2021 | +9.3% | — | — | |
| Q4 2021 | +9.3% | — | — | |
| Q3 2021 | -1.7% | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro